IGF-1 LR3
How to evaluate claims involving GHRP compounds, biomarkers, body composition, and recovery.
At a glance
- Evidence stage
- Preclinical
- Regulatory status
- IGF-1 LR3 is not FDA-approved for any use; research material sold under this name is not a regulated drug product.
- Research context
- IGF-1 LR3 is studied mainly in laboratory and animal (preclinical) performance & vitality research; mechanism and animal findings do not establish human safety or benefit.
What this is
- IGF-1 LR3 is discussed here as a subject of laboratory and animal (preclinical) research.
- Published findings focus on mechanism and early biology, not proven outcomes in people.
- IGF-1 LR3 is not an FDA-approved drug for any consumer, clinical, or performance use.
What this isn't
- This page is not medical advice or a treatment recommendation involving IGF-1 LR3.
- This is not a dosing guide — no dose, schedule, or administration instructions are implied.
- This is not proof that IGF-1 LR3 is safe or effective for use in humans.
Key terms
Educational information only — not medical advice. This material cannot diagnose a condition, recommend treatment, or replace care from a qualified clinician who knows your history. The Peptide Center uses an evidence-first editorial process that prioritizes primary regulatory sources, trial registries, and peer-reviewed research; uncertainty and evidence limits should be part of every health claim.
Growth-hormone secretagogue claims often begin with a biological pathway or a short-term laboratory measurement. Neither one establishes a meaningful health, performance, or recovery benefit. FDA has identified potential significant safety risks for several bulk substances in this category; review the FDA's current bulk-substances information for product-specific context.
Evidence limits
How to read the evidence
Educational information only — not medical advice. This material cannot diagnose a condition, recommend treatment, or replace care from a qualified clinician who knows your history. The Peptide Center uses an evidence-first editorial process that prioritizes primary regulatory sources, trial registries, and peer-reviewed research; uncertainty and evidence limits should be part of every health claim.
For any claimed outcome, ask whether it was measured directly, how long participants were followed, how harms were assessed, and whether the studied material and route match the claim being made. Do not infer safety from a mechanism or a testimonial.
Coverage
In the news
Recent reporting about this molecule. Headlines are not clinical guidance.
- In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptides - STATSTAT · 2026-07-23 · External ↗
- What to Know About Peptides the FDA Is Considering for Use - The New York TimesThe New York Times · 2026-07-23 · External ↗
- FDA advisers recommend relaxing US rules on compounding peptides - ReutersReuters · 2026-07-24 · External ↗
External sources and citations
- Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris. Applied microbiology and biotechnology, 2023
- Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets. Journal of developmental origins of health and disease, 2023
- IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep. American journal of physiology. Endocrinology and metabolism, 2025
- Design and characterisation of long-R3-insulin-like growth factor-I muteins which show resistance to pepsin digestion. Growth factors (Chur, Switzerland), 1996
- Sheep recombinant IGF-1 promotes organ-specific growth in fetal sheep. Frontiers in physiology, 2022
- Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig. The Journal of endocrinology, 1995
- Long [R3] insulin-like growth factor-I reduces growth, plasma growth hormone, IGF binding protein-3 and endogenous IGF-I concentrations in pigs. The Journal of endocrinology, 1997
- Endocrine and metabolic changes in neonatal calves in response to growth hormone and long-R3-insulin-like growth factor-I administration. Biology of the neonate, 1998
Common questions
What is IGF-1 LR3?
IGF-1 LR3 is discussed in research and educational contexts as a named molecule or product label. Identity, purity, and studied form can differ across sources — a name match alone is not proof of the same material used in a study.
What does the evidence for IGF-1 LR3 actually show?
Evidence for IGF-1 LR3 ranges by question: preclinical models, early human work, or approved uses for specific indications. Mechanism findings and animal data do not automatically predict clinical benefit or safety in people.
Is IGF-1 LR3 FDA-approved for general use?
Do not assume IGF-1 LR3 is FDA-approved for the use you have in mind. Approvals are indication-specific. Many research peptides and compounded products are not approved drugs for consumer or athletic use.
What product-quality questions should I ask about IGF-1 LR3?
Ask what was tested (identity, purity, potency), who tested it, and whether the label matches the studied form. Third-party certificates, storage conditions, and supplier transparency matter more than marketing claims.
How is IGF-1 LR3 different from similarly named products?
Blends, salts, fragments, and brand nicknames are often confused with IGF-1 LR3. Verify the exact molecule, dose unit, and route in any citation before treating it as evidence for a different product.
Related peptides
Other published briefs in the same research family. Educational references only - not treatment recommendations.
CJC-1295 No DAC
A framework for evaluating performance claims without treating a biological mechanism as proof of benefit.
Open resourcePeptide briefCJC-1295 No DAC / Ipamorelin
A framework for evaluating performance claims without treating a biological mechanism as proof of benefit.
Open resourcePeptide briefCJC-1295 With DAC
A framework for evaluating performance claims without treating a biological mechanism as proof of benefit.
Open resourcePeptide briefFollistatin 344
Why a compelling cell or animal result is the beginning of a question, not the end of it.
Open resourcePeptide briefGHRP-2
How to evaluate claims involving GHRP compounds, biomarkers, body composition, and recovery.
Open resourcePeptide briefGHRP-6
How to evaluate claims involving GHRP compounds, biomarkers, body composition, and recovery.
Open resourceLearn the research basics
Foundational literacy pieces that help interpret evidence stage, product identity, and study design.
How to read a peptide study without overclaiming
A practical guide to research stage, controls, endpoints, uncertainty, and applicability.
Open resourceLiteracyWhy a biological mechanism is not a treatment promise
A practical explanation of why plausible pathways still need meaningful human-outcome evidence.
Open resourceLiteracyPeptide naming, aliases, and product identity
Why the same acronym can refer to different molecules, salts, fragments, or blends.
Open resourceLiteracyFrom preclinical finding to human evidence
Why a compelling cell or animal result is the beginning of a question, not the end of it.
Open resourceLiteracyFDA approved, compounded, and unapproved are not synonyms
A plain-language map of product categories that are often blurred in peptide discussions.
Open resourceLiteracyUnderstanding surrogate endpoints in peptide research
When a laboratory value changes but patient outcomes remain uncertain.
Open resourceWatch & read
Same-family videos and articles from the Articles & Media channel. Educational references only.
Conor McGregor’s Injury: Diagnosis, Recovery, and How Peptides Could Help | Longevity University #02
Two weeks after their last conference, Dr. Rehan and Milan are back in Las Vegas for Milan's birthday and a UFC card that ended in one of the most talked-about injuries of the year: Conor McGregor's leg buckling on his very first strike. In this episode, Dr. Rehan gives his thoughts on why he's leaning toward a full-thickness ACL tear over a meniscus injury, and what a realistic recovery timeline looks like for a fighter coming back from five years out. After that, Dr. Rehan gives the exact protocol he would put McGregor on if he does in fact need ACL surgery. From there the guys get into Paddy Pimblett's clinical finish, that fighter's brutal weight cuts, Max Holloway's night, and why "movement practice" athletes like McGregor seem to age better than everyone else. 01:35 Vegas, Milan's birthday & watching McGregor go down 02:41 The diagnosis: why it looks like a full ACL tear 07:14 Realistic recovery timeline & what surgery can't skip 09:26 Where peptides actually help before and after surgery 11:16 The full protocol Dr. Rehan would run for McGregor 13:57 Sponsor: XYRx (code LU10) 14:39 BPC-157 and TB-500 explained 17:17 The drug-testing pool problem 18:48 ACL vs. meniscus & why surgery is unavoidable 22:49 Paddy Pimblett's finish, his camp & those weight cuts 29:48 Max Holloway, the Vegas weekend & Conor's comeback odds Every week, Physician Dr. Rehan Muttalib and XYRx founder Milan Costich on the real science of male longevity: peptides, GLP-1s, training, and recovery. Longevity University YouTube: youtube.com/@LongevityUniversity Instagram: instagram.com/longevityunversity_ TikTok: tiktok.com/@longevityuniversity X: x.com/longevityupod Dr. Rehan Instagram: instagram.com/askDr.Rehan TikTok: https://www.tiktok.com/@askdrrehan X: x.com/askdrrehan Milan Instagram: instagram.com/milancostich TikTok: tiktok.com/@milancostich X: x.com/MilanCostich_ Support our sponsor (and the Milan and Dr. Rehan's company) XYRx.co XYRx YouTube: youtube.com/@XYRxHealth
Open resourceVideoI Injected 5 Peptides for 30 Days to Kill My Cortisol (Full Results)
All my bloodwork and protocols are done through https://otmens.com Free consults available now in all 50 states ⏱ TIMESTAMPS: 00:00 - Chronic stress 02:48 - Cortisol dangers 05:11 - Epithalon 07:23 - Selank 08:39 - Semax 09:21 - Wolverine Blend 10:12 - SS-31 & MOTS-c 11:04 - Core supplements 12:51 - Lifestyle habits 📱 Connect with me on other platforms: https://www.tiktok.com/@jacobnach https://www.instagram.com/jacobnach/ https://www.instagram.com/otmenshealth/ ⚠️ DISCLAIMER: This YouTube channel does not contain medical advice. I am not a doctor, licensed physician, or medical professional. The content provided on this channel is for entertainment and informational purposes only. Any discussion on this page is my personal experience and subjective opinions only. These are not recommendations for you to follow. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or the use of experimental compounds.
Open resourceVideoPeptide & Hormone Therapies for Health, Performance & Longevity | Dr. Craig Koniver
In this episode, Dr. Craig Koniver, M.D., a board-certified physician trained at Brown University and Thomas Jefferson University, discusses the therapeutic application of peptides and hormones for enhancing physical and mental health and performance. We explore GLP-1 analogs for weight loss, BPC-157 for wound healing and reducing inflammation, as well as peptides that increase growth hormone, improve REM sleep, and enhance cognitive function. We also cover testosterone therapy, NAD, NMN, and NR supplementation, methylene blue for mitochondrial health, stem cell therapies, and supplements such as CoEnzyme Q10 and methylated B vitamins. Additionally, we discuss effective dosages, sourcing, safety considerations, and the importance of working with knowledgeable physicians. Whether you're currently using peptides or exogenous hormones, or simply curious about their potential benefits and risks, this episode provides the scientific rationale behind how peptides function, their potential to enhance mental and physical health, and how they can optimize performance. Access the full show notes for this episode: https://go.hubermanlab.com/Nya6k2f Pre-order Andrew's book, Protocols: https://go.hubermanlab.com/protocols Use Ask Huberman Lab, our chat-based tool, for summaries, clips, and insights from this episode: https://go.hubermanlab.com/tqqZoQT *Thank you to our sponsors* AG1: https://drinkag1.com/huberman Joovv: https://joovv.com/huberman BetterHelp: https://betterhelp.com/huberman Function: https://functionhealth.com/huberman Eight Sleep: https://eightsleep.com/huberman *Dr. Craig Koniver* Koniver Wellness: https://koniverwellness.com Koniver Aesthetics: https://koniveraesthetics.com Instagram: https://www.instagram.com/koniverwellness LinkedIn: https://www.linkedin.com/in/craig-koniver-md-4bb100126 *Timestamps* 00:00:00 Dr. Craig Koniver 00:04:52 Sponsors: Joovv & BetterHelp 00:07:40 What is a Peptide? 00:09:37 GLP-1 Agonists, Semaglutide Weight Loss, B
Open resourceVideoMost Powerful Peptide for Muscle Building and Physical Performance (Mitochondria Enhancer)
Use Code THOMAS25 for 25% off Your First Order from SEED: https://www.seed.com/thomasyt This video does contain a paid partnership with a brand that helps to support this channel. It is because of brands like this that we are able to provide the content that we do for free. Click HERE to Subscribe: https://www.youtube.com/c/ThomasDeLauerOfficial?sub_confirmation=1 Please check out the new Shorts channel, DeLauer Clips and Workouts, here: https://www.youtube.com/channel/UCQPQImPsw74KhO0Zy2-leyA/videos Please Subscribe to my Email Newsletter Here: https://www.thomasdelauer.com/life-optimization-tactics/ Follow More of My Daily Life on Instagram: http://www.Instagram.com/ThomasDeLauer References https://www.nature.com/articles/s41467-020-20790-0 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238132/ Timestamps ⏱ 0:00 - Intro 0:45 - 25% off Your First Order from SEED 1:40 - Performance Benefits 4:09 - Muscle-Building Effects 6:52 - Viable Candidates for MOTS-C
Open resourceArticleSermorelin: growth-hormone secretagogue research
Evaluating sermorelin claims without treating a GH-releasing peptide narrative as proof of benefit.
Open resourceRelated articles
Same-family articles from the published library. Educational references only - not treatment recommendations.